Whilst it is true that Althea are probably the most prescribed cannabis medication in Australia, it is meaningless in the long term.
Cannabis prescribed under the SAS will become redundant when TGA / FDA approved cannabinoid medications are approved.
Now that epidiolex has been FDA and EMA approved, it's only a matter of time before it is TGA approved too.
This creates an opportunity for an accelerated pathway for any other bioequivalent drugs for other therapeutic areas.
You could say that AGH/ BDA/ MXC fighting for the SAS sales are wasting time and money as it will be replaced as soon as the TGA approved ones are available. TGA/ FDA/ EMA have all got accelerated pathways and there are already over a dozen of these cannabinoid drugs in the approval process as we speak.
It's a short term capital markets story which will be immediately made redundant when there are approved drugs on the TGA ARTG.
AGH Price at posting:
39.0¢ Sentiment: None Disclosure: Held
